FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018506244> ?p ?o ?g. }

• W2018506244 endingPage "33" @default.
• W2018506244 startingPage "25" @default.
• W2018506244 abstract "Despite the hepatic arterial infusion chemotherapy (HAI) has been advocated as an effective therapy for hepatocellular carcinoma (HCC) with multiple intrahepatic metastases, Chemosensitivity of HCC for HAI with multidrug regimen has not been sufficiently investigated. The purpose of this study was to evaluate the in vitro chemosensitivity of HCC using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-Biphenyl-2H tetrazolium bromide (MTT) assay with the combinations of various antitumor drugs, and compared with the clinical results of HAI for patients with multiple intrahepatic recurrences of HCC. To evaluate the in vitro Chemosensitivity of HOC to the combinations of antitumor drugs, 54 resected specimens of HCC were assayed using MTT assay with seven antitumor agents, 5-fluorouracil (5-FU), mitomycin C (MMC), adriamycin (ADM), etoposide (VP-16), cisplatin (CDDP), methotrexate (MTX) and CPT-11 (SN-38), exposed singly, or in combination. The data were compared with the clinical results of HAI for patients who manifested the multiple intrahepatic recurrence. In addition, the in vitro combined effect of CDDP and 5-FU for human hepatocellular carcinoma cell, KYN-1 and KYN-2, was analysed quantitatively. Of 54 resected specimens, 40 specimens assayed successfully, and an increased in vitro chemosensitivity of HCC when treated with combinations of antitumor drugs was observed: single drug 12.2%, two drugs combined 50.9% and three drugs combined 67.0%. The results of in vitro assay were well correlated, 85.7% in predicting accuracy, with the clinical results of 14 patients who underwent HAI for multiple recurrence of HCC, and also correlated with the experimental results of the combined use of CDDP and 5-FU in KYN-1 and KYN-2 in terms of pharmacokinetic reactions, i.e. synergism or antagonism. The MTT assay with the combinations of antitumor drugs represents an informative chemosensitivity test to HAI with multidrug regimen for recurrence of HCC." @default.
• W2018506244 created "2016-06-24" @default.
• W2018506244 creator A5052196846 @default.
• W2018506244 date "2004-01-01" @default.
• W2018506244 modified "2023-09-23" @default.
• W2018506244 title "In vitro Chemosensitivity of Hepatocellular Carcinoma for Hepatic Arterial Infusion Chemotherapy Using the MTT Assay with the Combinations of Antitumor Drugs" @default.
• W2018506244 cites W149131099 @default.
• W2018506244 cites W1648778265 @default.
• W2018506244 cites W1886323865 @default.
• W2018506244 cites W1967595077 @default.
• W2018506244 cites W1986414102 @default.
• W2018506244 cites W1986534365 @default.
• W2018506244 cites W1988400082 @default.
• W2018506244 cites W1993685604 @default.
• W2018506244 cites W1994528794 @default.
• W2018506244 cites W2000540782 @default.
• W2018506244 cites W2005498062 @default.
• W2018506244 cites W2015674331 @default.
• W2018506244 cites W2015751526 @default.
• W2018506244 cites W2018329764 @default.
• W2018506244 cites W2038373593 @default.
• W2018506244 cites W2042470623 @default.
• W2018506244 cites W2044561937 @default.
• W2018506244 cites W2067847611 @default.
• W2018506244 cites W2072259837 @default.
• W2018506244 cites W2074333538 @default.
• W2018506244 cites W2077945404 @default.
• W2018506244 cites W2093599180 @default.
• W2018506244 cites W2107008135 @default.
• W2018506244 cites W2114918609 @default.
• W2018506244 cites W2120064876 @default.
• W2018506244 cites W2129105829 @default.
• W2018506244 cites W2137310322 @default.
• W2018506244 cites W2140927361 @default.
• W2018506244 cites W2161417398 @default.
• W2018506244 cites W2167805334 @default.
• W2018506244 cites W2225180760 @default.
• W2018506244 cites W2308372592 @default.
• W2018506244 cites W2315948693 @default.
• W2018506244 cites W2404009483 @default.
• W2018506244 cites W2412249834 @default.
• W2018506244 cites W2419506202 @default.
• W2018506244 doi "https://doi.org/10.2739/kurumemedj.51.25" @default.
• W2018506244 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15150897" @default.
• W2018506244 hasPublicationYear "2004" @default.
• W2018506244 type Work @default.
• W2018506244 sameAs 2018506244 @default.
• W2018506244 citedByCount "12" @default.
• W2018506244 countsByYear W20185062442013 @default.
• W2018506244 countsByYear W20185062442016 @default.
• W2018506244 countsByYear W20185062442017 @default.
• W2018506244 countsByYear W20185062442018 @default.
• W2018506244 countsByYear W20185062442020 @default.
• W2018506244 crossrefType "journal-article" @default.
• W2018506244 hasAuthorship W2018506244A5052196846 @default.
• W2018506244 hasBestOaLocation W20185062441 @default.
• W2018506244 hasConcept C126322002 @default.
• W2018506244 hasConcept C141071460 @default.
• W2018506244 hasConcept C185592680 @default.
• W2018506244 hasConcept C202751555 @default.
• W2018506244 hasConcept C2776694085 @default.
• W2018506244 hasConcept C2778019345 @default.
• W2018506244 hasConcept C2778076430 @default.
• W2018506244 hasConcept C2778119113 @default.
• W2018506244 hasConcept C2778239845 @default.
• W2018506244 hasConcept C2779338040 @default.
• W2018506244 hasConcept C2780783641 @default.
• W2018506244 hasConcept C2781303535 @default.
• W2018506244 hasConcept C55493867 @default.
• W2018506244 hasConcept C71924100 @default.
• W2018506244 hasConcept C98274493 @default.
• W2018506244 hasConceptScore W2018506244C126322002 @default.
• W2018506244 hasConceptScore W2018506244C141071460 @default.
• W2018506244 hasConceptScore W2018506244C185592680 @default.
• W2018506244 hasConceptScore W2018506244C202751555 @default.
• W2018506244 hasConceptScore W2018506244C2776694085 @default.
• W2018506244 hasConceptScore W2018506244C2778019345 @default.
• W2018506244 hasConceptScore W2018506244C2778076430 @default.
• W2018506244 hasConceptScore W2018506244C2778119113 @default.
• W2018506244 hasConceptScore W2018506244C2778239845 @default.
• W2018506244 hasConceptScore W2018506244C2779338040 @default.
• W2018506244 hasConceptScore W2018506244C2780783641 @default.
• W2018506244 hasConceptScore W2018506244C2781303535 @default.
• W2018506244 hasConceptScore W2018506244C55493867 @default.
• W2018506244 hasConceptScore W2018506244C71924100 @default.
• W2018506244 hasConceptScore W2018506244C98274493 @default.
• W2018506244 hasIssue "1" @default.
• W2018506244 hasLocation W20185062441 @default.
• W2018506244 hasLocation W20185062442 @default.
• W2018506244 hasOpenAccess W2018506244 @default.
• W2018506244 hasPrimaryLocation W20185062441 @default.
• W2018506244 hasRelatedWork W1993685604 @default.
• W2018506244 hasRelatedWork W2005120423 @default.
• W2018506244 hasRelatedWork W2059524192 @default.
• W2018506244 hasRelatedWork W2085562186 @default.
• W2018506244 hasRelatedWork W2336451035 @default.
• W2018506244 hasRelatedWork W2366653713 @default.
• W2018506244 hasRelatedWork W2390991979 @default.

• next